Literature DB >> 11979358

Nephrotic syndrome after treatment with pamidronate.

Glen S Markowitz1, Paul L Fine, Vivette D D'agati.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11979358     DOI： 10.1053/ajkd.2002.32797

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  13 in total

1.  Tolerability of intravenous pamidronate for the treatment of osteoporosis and other metabolic osteopathies: A retrospective analysis.

Authors:  Marcelo Sarli; Rodolfo Spivacow; Viviana Pedroarias; Emilio J A Roldán; José R Zanchetta
Journal:  Curr Ther Res Clin Exp       Date:  2007-01

Review 2.  Side effects of bone-targeted therapies in advanced breast cancer.

Authors:  Christoph Domschke; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

3.  Nephrotic syndrome induced by pamidronate.

Authors:  M A G J ten Dam; L B Hilbrands; J F M Wetzels
Journal:  Med Oncol       Date:  2010-09-24       Impact factor: 3.064

4.  Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate.

Authors:  J Pascual; J Torrealba; J Myers; S Tome; M Samaniego; A Musat; A Djamali
Journal:  Osteoporos Int       Date:  2007-04-03       Impact factor: 4.507

Review 5.  Drug-induced glomerular disease: direct cellular injury.

Authors:  Glen S Markowitz; Andrew S Bomback; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-10       Impact factor: 8.237

6.  Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.

Authors:  Kyriaki Mystakidou; Evangelia Stathopoulou; Efi Parpa; Vassilios Kouloulias; Evangelia Kouskouni; Lambros Vlahos
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-27       Impact factor: 4.553

7.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Authors:  Evangelos Terpos; Gareth Morgan; Meletios A Dimopoulos; Matthew T Drake; Suzanne Lentzsch; Noopur Raje; Orhan Sezer; Ramón García-Sanz; Kazuyuki Shimizu; Ingemar Turesson; Tony Reiman; Artur Jurczyszyn; Giampaolo Merlini; Andrew Spencer; Xavier Leleu; Michele Cavo; Nikhil Munshi; S Vincent Rajkumar; Brian G M Durie; G David Roodman
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

8.  Reversibility of pamidronate-associated glomerulosclerosis.

Authors:  Meera Shreedhara; Andrew Z Fenves; Diana Benavides; Marvin J Stone
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

9.  Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

Authors:  Danielle E Robinson; M Sanni Ali; Victoria Y Strauss; Leena Elhussein; Bo Abrahamsen; Nigel K Arden; Yoav Ben-Shlomo; Fergus Caskey; Cyrus Cooper; Daniel Dedman; Antonella Delmestri; Andrew Judge; Muhammad Kassim Javaid; Daniel Prieto-Alhambra
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

10.  Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients.

Authors:  Dimitrios Chantzichristos; Björn Andréasson; Peter Johansson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.